|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1997-5-28
|
|
pubmed:abstractText |
Patients with Hodgkin's disease (HD) and intermediate or high-grade non-Hodgkin's lymphoma (NHL) who fail to achieve a complete remission (CR) with standard induction therapy have a poor prognosis with conventional-dose salvage therapy alone. We examined the role of subsequent intensive therapy and autologous bone marrow transplantation (ABMT) in patients who demonstrated a response to conventional-dose therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BrandweinJ MJM,
pubmed-author:CarstairsKK,
pubmed-author:CrumpMM,
pubmed-author:GirouardCC,
pubmed-author:ImrieKK,
pubmed-author:KeatingAA,
pubmed-author:PantalonyDD,
pubmed-author:PrinceH MHM,
pubmed-author:ScottGG,
pubmed-author:StewartA KAK,
pubmed-author:SutcliffeSS,
pubmed-author:SuttonD MDM,
pubmed-author:TsangRR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1043-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9037363-Adolescent,
pubmed-meshheading:9037363-Adult,
pubmed-meshheading:9037363-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9037363-Bone Marrow Transplantation,
pubmed-meshheading:9037363-Combined Modality Therapy,
pubmed-meshheading:9037363-Female,
pubmed-meshheading:9037363-Hodgkin Disease,
pubmed-meshheading:9037363-Humans,
pubmed-meshheading:9037363-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9037363-Male,
pubmed-meshheading:9037363-Middle Aged,
pubmed-meshheading:9037363-Salvage Therapy,
pubmed-meshheading:9037363-Survival Rate,
pubmed-meshheading:9037363-Transplantation, Autologous,
pubmed-meshheading:9037363-Transplantation Conditioning
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma.
|
|
pubmed:affiliation |
University of Toronto Autologous Blood and Marrow Transplant Program, Toronto Hospital, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article
|
